Cohance Lifesciences Intrinsic Value

Cohance Lifesciences (COHANCE) median intrinsic value is ₹823.47 from 8 valuation models (range ₹132–₹1101), vs current price ₹440.20 — +87.1% upside (Trading Below Calculated Value), margin of safety 46.5%. For current market price and key ratios, visit Cohance Lifesciences share price screener.

Market Price (CMP)
₹440.20
Primary Intrinsic Value
₹132.06
Market Cap
₹1673 Cr
+87.1% Upside
Median Value
₹823.47
Value Range
₹132 - ₹1101
Assessment
Trading Below Calculated Value
Safety Margin
46.5%

COHANCE Valuation Methods Summary — DCF, Graham Number & P/E

Cohance Lifesciences intrinsic value across 8 models vs current price ₹440.20 — upside/downside and value range per method. Check COHANCE market value to track the company's total market size over time.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹132.06 ₹105.65 - ₹158.47 -70.0% EPS: ₹2.04, Sector P/E: 22x
Book Value Method asset ₹1100.50 ₹990.45 - ₹1210.55 +150.0% Book Value/Share: ₹1061.58, P/B: 2.0x
Revenue Multiple Method revenue ₹880.40 ₹792.36 - ₹968.44 +100.0% Revenue/Share: ₹649.47, P/S: 2.0x
EBITDA Multiple Method earnings ₹842.11 ₹757.90 - ₹926.32 +91.3% EBITDA: ₹320.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹823.47 ₹658.78 - ₹988.16 +87.1% CF Growth: 2.8%, Discount: 15%
PEG Ratio Method growth ₹132.06 ₹118.85 - ₹145.27 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹132.06 ₹118.85 - ₹145.27 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
Graham Defensive Method conservative ₹220.74 ₹198.67 - ₹242.81 -49.9% EPS: ₹2.04, BVPS: ₹1061.58
Method Types: Earnings Asset DCF Growth Dividend Conservative

COHANCE Intrinsic Value vs Market Price — All Valuation Models

Cohance Lifesciences fair value range ₹132–₹1101 vs current market price ₹440.20 across 8 valuation models. See COHANCE P/B ratio to compare market price against book value per share.

COHANCE Intrinsic Value Analysis — Undervalued or Overvalued?

Cohance Lifesciences median intrinsic value ₹823.47, current price ₹440.20 — Trading Below Calculated Value by 87.1%, margin of safety 46.5%.

What is the intrinsic value of COHANCE?

Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹823.47 (median value). With the current market price of ₹440.20, this represents a +87.1% variance from our estimated fair value.

The valuation range spans from ₹132.06 to ₹1100.50, indicating ₹132.06 - ₹1100.50.

Is COHANCE undervalued or overvalued?

Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading below calculated value by approximately 87.1%.

COHANCE Financial Health — Key Ratios vs Industry Benchmarks

Cohance Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 1.71 Industry Standard: 2.0+ Above 1.5 Measures short-term liquidity capacity
Return on Equity 0.8% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 13.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.43x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

COHANCE Cash Flow Quality — Operating & Free Cash Flow

Cohance Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹368 Cr ₹243 Cr Positive Free Cash Flow 8/10
March 2025 ₹673 Cr ₹479 Cr Positive Free Cash Flow 8/10
March 2024 ₹359 Cr ₹178 Cr Positive Free Cash Flow 7/10
March 2023 ₹457 Cr ₹360 Cr Positive Free Cash Flow 8/10
March 2022 ₹330 Cr ₹262 Cr Positive Free Cash Flow 8/10